Dapagliflozin: All-Cause & Cardiovascular Mortality


Research has shown the beneficial effects of empagliflozin on all-cause and CV mortality. Does the same hold true for another SGLT2 inhibitor?

The beneficial effects of empagliflozin have been published as it relates to all-cause and cardiovascular mortality. Do these effects hold true for other SGLT2 inhibitors?

The study, published in The Journal of Clinical Endocrinology and Metabolism, was a retrospective cohort study of over 22,000 patients with T2DM from the UK in The Health Improvement Network Database (Jan 2013 – Sept 2015). Researchers compared exposed patients (those given dapagliflozin) to unexposed patients (dapagliflozin-naïve).

Patients on dapagliflozin were significantly less likely to die from any cause, regardless of baseline cardiac risk.

Related Videos
A panel of 5 experts on Cushing's syndrome
A panel of 5 experts on Cushing's syndrome
Laxmi Mehta, MD | Credit: American Heart Association
Reviewing 2023 with FDA Commissioner Robert M. Califf, MD
Erin Michos, MD | Credit: Johns Hopkins University
© 2024 MJH Life Sciences

All rights reserved.